Cost-effective management of heart failure

Clinical Cardiology

Volumn 19, Issue 3, 1996, Pages 240-242

  Parmley, William W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Medical Center at Parnassus   (United States)

Author keywords

angiotensin converting enzyme inhibitor; cost; heart failure; hospitalization

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALGORITHM; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE UTILIZATION; HEART FAILURE; HOME CARE; HOSPITALIZATION; MEDICAL PRACTICE; NURSING HOME; REVIEW; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0029813402     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190319     Document Type: Review

References (14)

1. Heart Failure: Evaluation and Care of Patients with Left Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11, U.S. Department of Health and Human Services, AHCPR publication No. 94-0612, June 1994
2. Thom T (National Heart, Lung, and Blood Institute): Letter to David C Hadorn. Written communication: April 12, 1993
3. Levit KR, Lazenby HC, Cowan CA, Letsch SW: National health expenditures, 1990. Health Care Fin Rev 1991 ; 13:29-54
4. National Center for Health Statistics: Detailed Diagnoses and Procedures, National Hospital Discharge Survey, 1990. Vital and Health Statistics, Series 13, No. 113. Hyattsville (Md.): The Center; DHHS publication No. 92-1774, 1992
5. National Center for Health Statistics: National Ambulatory Medical Care Survey, 1989 Summary. Vital and Health Statistics. Series 13, No. 110. Hyattsville (Md.): The Center. DHHS publication No. (PHS) 92-1771, 1992
6. National Center for Health Statistics: Discharges from Nursing Homes: 1985 National Nursing Home Survey. Vital and health statistics, Series 13, No. 103. Hyattsville (Md.): The Center; DHHS publication No. (PHS) 90-1764
7. Fleg JL, Hinton PC, Lakatta EG, Marcus FI, Smith TW, Strauss HC, Hlatky MA: Physician utilization of laboratory procedures to monitor outpatients with congestive heart failure. Arch Intern Med 1989; 149:393-396
8. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J Am Med Assoc 1995; 273:1450-1456
9. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Sanders R, Fletcher RD, Loeb HS, Hughes VC, Baker B: Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-1552
10. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bonmer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, Demets, DL: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-1475
11. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691
12. CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316:1429-1435
13. SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685-691
14. Tobin JR: The treatment of congestive heart failure: Digitalis glycosides are still the primary mode of therapy. Arch Intern Med 1978; 138:453-454